Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery. It is in a class of medications called 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products
FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran)
FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron)[ARCHIVED]
FDA Drug Safety Podcast for Healthcare Professionals: Abnormal heart rhythms may be associated with use of Zofran (ondansetron)[ARCHIVED]